Sartorius Biotech GmbH Release: New Webinar On Integrating DoE Tools And ambr 15 Micro Bioreactors
Featuring a Case Study Showing how this Combined Technology can Reduce Timelines for Process Optimisation
Cambridge, UK – March 4, 2015: Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar on Wednesday, March 18th at 9am GMT (10am CET / 2.30pm IST/ 5pm China Standard Time) and again at 4pm GMT (8am PST/11am EST). The live events will detail how to use the new ambr® 15 automated micro bioreactor system with integrated BioPAT® MODDE Software for Design of Experiments (DoE) to make bioprocess optimisation both quicker and easier.
Bioprocessing expert, Dr Barney Zoro, ambr 15 Product Manager at SSB, will introduce the ambr 15 system and its use as an automated small scale cell culture mimic, as well as provide an overview of the integrated BioPAT MODDE Software.
During the 40 minute webinar, Zoro will describe the functional features of the ambr 15 system with its multiple single-use micro bioreactors (10-15mL), controlled by an automated workstation. He will then outline how the BioPAT MODDE software has been integrated into the ambr 15 system to enable users to rapidly generate DoE experiments via work packets and configure each micro bioreactor with its own DoE defined bioprocessing parameters. Zoro will then demonstrate how this can accelerate process development to larger single-use BIOSTAT® pilot and manufacturing scale bioreactors using a DoE case study.
To register for these live webinars, scientists can visit:
http://www.tapbiosystems.com/ambr_webinar/ambrdoe_webinarpr.htm
Dr Barney Zoro, ambr15 Product Manager at SSB stated: "Many scientists across the biopharm industry are successfully using the ambr 15 system to speed up their process development. Integrating the BioPAT MODDE Software into the ambr 15 will allow these scientists to rapidly implement DoE into their work flow and I am delighted to be hosting a webinar to discuss this exciting advance.”
Zoro added: “I look forward to explaining how these combined technologies can reduce timelines for process optimisation and scale-up, ensuring more cost-effective manufacturing of biologics and vaccines.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
ambr® systems are designed and manufactured by TAP Biosystems (now part of the Sartorius Stedim Biotech Group) a leading global provider of automated cell culture and fermentation systems for life science research, development and production. ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.
Help employers find you! Check out all the jobs and post your resume.
Cambridge, UK – March 4, 2015: Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar on Wednesday, March 18th at 9am GMT (10am CET / 2.30pm IST/ 5pm China Standard Time) and again at 4pm GMT (8am PST/11am EST). The live events will detail how to use the new ambr® 15 automated micro bioreactor system with integrated BioPAT® MODDE Software for Design of Experiments (DoE) to make bioprocess optimisation both quicker and easier.
Bioprocessing expert, Dr Barney Zoro, ambr 15 Product Manager at SSB, will introduce the ambr 15 system and its use as an automated small scale cell culture mimic, as well as provide an overview of the integrated BioPAT MODDE Software.
During the 40 minute webinar, Zoro will describe the functional features of the ambr 15 system with its multiple single-use micro bioreactors (10-15mL), controlled by an automated workstation. He will then outline how the BioPAT MODDE software has been integrated into the ambr 15 system to enable users to rapidly generate DoE experiments via work packets and configure each micro bioreactor with its own DoE defined bioprocessing parameters. Zoro will then demonstrate how this can accelerate process development to larger single-use BIOSTAT® pilot and manufacturing scale bioreactors using a DoE case study.
To register for these live webinars, scientists can visit:
http://www.tapbiosystems.com/ambr_webinar/ambrdoe_webinarpr.htm
Dr Barney Zoro, ambr15 Product Manager at SSB stated: "Many scientists across the biopharm industry are successfully using the ambr 15 system to speed up their process development. Integrating the BioPAT MODDE Software into the ambr 15 will allow these scientists to rapidly implement DoE into their work flow and I am delighted to be hosting a webinar to discuss this exciting advance.”
Zoro added: “I look forward to explaining how these combined technologies can reduce timelines for process optimisation and scale-up, ensuring more cost-effective manufacturing of biologics and vaccines.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
ambr® systems are designed and manufactured by TAP Biosystems (now part of the Sartorius Stedim Biotech Group) a leading global provider of automated cell culture and fermentation systems for life science research, development and production. ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.
Help employers find you! Check out all the jobs and post your resume.